Associate
Yoonjin has a wide range of technical experience, including the areas of inorganic chemistry, chemical biology, drug discovery, molecular and cellular biology, gene therapy, antibody development and therapies, diagnostic markers, and therapies for metabolic diseases. Prior to joining Finnegan, Yoonjin worked as a post-doctoral researcher at Dana-Farber Cancer Institute, investigating glucose and other macronutrients metabolism.
Yoonjin's graduate research focused on designing a high throughput chemical screen, discovering potential drug targets for type II diabetes, and understanding the molecular mechanism of glucose homeostasis. Before her graduate studies, Yoonjin was an undergraduate researcher at Ewha Womans University, where she studied enzymatic properties of oxoiron (IV) non-heme models utilizing analytical and characterization tools. She was also a teaching fellow in the Department of Chemistry and Chemical Biology at Harvard University, where she instructed undergraduate students in organic chemistry.
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Representing Eli Lilly in litigation involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of a team representing Eli Lilly in multiple inter partes review proceedings involving antibody therapies.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Member of a team that represented Eli Lilly in multiple Federal Circuit appeals.
2020-1747, -1748, -1749, -1750, -1751, -1752, -1876, -1877, -1878, Fed. Cir.
Sandoz, Inc. et al v. Pharmacyclics LLC
Member of a team that represented patent owner in inter partes review (IPR) challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.
IPR2019-00865, PTAB, Judges Cotta, Snedden, Mitchell
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.